BioSpace News Archive

Drug Development

Boehringer Ingelheim and Lilly’s Jardiance Scores in Late-Stage CKD Trial

Eli Lilly’s and Boehringer’s Jardiance met its primary outcome in the Phase III EMPA-KIDNEY study, the largest and broadest SGLT2 inhibitor trial in chronic kidney disease.

November 7, 2022
·
3 min read
·
Tristan Manalac
Dietary Supplements Fall Short vs. Astra’s Crestor in Lowering Cholesterol - Updated

Six supplements commonly taken to improve heart health and lower high cholesterol were ineffective when compared to AstraZeneca’s Crestor (rosuvastatin) and placebo.

November 7, 2022
·
4 min read
·
Rosemary Scott
Drug Development

GSK’s Blenrep for Multiple Myeloma Misses Mark in Phase III Confirmatory Trial

GSKs Blenrep misses the mark in the Phase III DREAMM-3 trial for relapsed or refractory multiple myeloma (RRMM), possibly putting the drug’s continued approval at risk.

November 7, 2022
·
3 min read
·
Mark Terry
Drug Development

Roche/Ionis, Chinook and Vera Eye Phase III in IgAN

Biopharma’s efforts to conquer immunoglobulin A nephropathy were on full display at ASN’s Kidney Week as Ionis, Chinook and Vera all reported positive data.

November 7, 2022
·
3 min read
·
Alex Keown
Drug Development

Only Patient in N-of-1 CRISPR Trial for Duchenne Muscular Dystrophy Dies

The only patient in an FDA-sanctioned clinical trial assessing a CRISPR-based therapy for a rare form of Duchenne muscular dystrophy has died, according to study sponsor Cure Rare Disease.

November 7, 2022
·
2 min read
·
Alex Keown
Business

Sensorium Scores $30M to Change Risk-Value Proposition in CNS Drug Discovery

Sensorium Therapeutics, which closed a $30 million Series A Tuesday, is embracing the complexity of neuropsychiatric diseases with nature-inspired psychoactive medicines.

November 7, 2022
·
4 min read
·
Heather McKenzie
Deals

Viatris Acquires Oyster Point, Gains Access to Ophthalmic Pipeline

Eye specialist Oyster Point Pharma announced is being acquired by Viatris Inc. after Oyster’s board of directors unanimously signed off on the deal, Oyster Point announced Monday.

November 7, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Verve and Beam Face Regulatory Roadblocks with Next-Gen Base Editors

Verve Therapeutics’ base editing program has been forced into a detour after the FDA placed a hold on its investigational new drug application. Beam has also posted its own regulatory update.

November 7, 2022
·
3 min read
·
Kate Goodwin
What to Do if Salary Transparency Laws Have Left You Feeling Underpaid

Salary transparency laws are becoming more popular across the U.S. Here are some tips to help you negotiate your pay when salary transparency has left you feeling underpaid.

November 7, 2022
·
4 min read
·
Franklin Carpenter
Business

Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease, today announced that the Company will report its financial results for the third quarter 2022 on Monday, November 14, 2022.

November 7, 2022
·
1 min read